Article
Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma.
ESMO open - 1 Nov 2020
Seeber Andreas, Zimmer Kai, Kocher Florian, Puccini Alberto, Xiu Joanne, Nabhan Chadi, Elliott Andrew, Goldberg Richard M, Grothey Axel, Shields Anthony F, Battaglin Francesca, El-Deiry Wafik S, Philip Philip A, Marshall John L, Hall Michael, Korn W Michael, Lenz Heinz-Josef, Wolf Dominik, Feistritzer Clemens, Spizzo Gilbert
Abstract excerpt
INTRODUCTION: Poly-(ADP)-ribose polymerase (PARP) inhibitors are successfully used for treatment of BRCA-mutated (mut) breast cancers and are under extensive evaluation for BRCA- and PALB2-mutated pancreatic ductal adenocarcinoma (PDAC). However, the optimal treatment regimen for BRCA/PALB2-mutated PDCA has yet to be established. Moreover, limited data are available on the association of BRCA/PALB2 gene...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.